Brief: Adaptimmune Reports Positive Results From Its Pivotal Trial In Patients With Synovial Sarcoma And MRCLS
11/11/2021 14:08
Nov 11 (Reuters) - Adaptimmune Therapeutics PLC ADAP.O :
* ADAPTIMMUNE REPORTS POSITIVE RESULTS FROM ITS PIVOTAL
SPEARHEAD-1 TRIAL IN PATIENTS WITH SYNOVIAL SARCOMA AND MRCLS AT
CTOS
* ADAPTIMMUNE THERAPEUTICS PLC - SPEARHEAD-1 TRIAL WILL MEET
ITS
PRIMARY ENDPOINT AND DATA WILL BE USED TO SUPPORT BLA FILING FOR
AFAMI-CEL NEXT YEAR
Source text for Eikon: ID:nGNX12FnDM
Further company coverage: ADAP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adaptimmune Therapeutics
See all newsAdaptimmune Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 10 cents a share - Earnings Preview
Enters Settlement Agreement With MD Anderson - SEC Filing
Adaptimmune Therapeutics PLC reports results for the quarter ended March 31 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 12 cents a share - Earnings Preview